Rachel Vatnsdal
Stock Analyst at JP Morgan
(3.54)
# 848
Out of 5,123 analysts
68
Total ratings
58.7%
Success rate
19.58%
Average return
Main Sectors:
Stocks Rated by Rachel Vatnsdal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RVTY Revvity | Maintains: Neutral | $100 → $105 | $99.52 | +5.51% | 5 | Feb 3, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $17 → $20 | $16.47 | +21.43% | 6 | Nov 6, 2025 | |
| HSIC Henry Schein | Maintains: Overweight | $80 → $76 | $77.00 | -1.30% | 4 | Aug 7, 2025 | |
| AVTR Avantor | Maintains: Overweight | $17 → $14 | $10.79 | +29.75% | 1 | Aug 4, 2025 | |
| ILMN Illumina | Maintains: Neutral | $85 → $100 | $133.61 | -25.16% | 1 | Aug 1, 2025 | |
| CAI Caris Life Sciences | Initiates: Overweight | $31 | $21.25 | +45.88% | 1 | Jul 14, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $9 | $17.70 | -49.15% | 4 | May 9, 2025 | |
| TWST Twist Bioscience | Maintains: Underweight | $40 → $33 | $47.10 | -29.94% | 2 | May 6, 2025 | |
| RGEN Repligen | Maintains: Overweight | $200 → $190 | $139.66 | +36.04% | 6 | Apr 29, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $20 → $19 | $24.71 | -23.11% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $380 → $390 | $376.89 | +3.48% | 4 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $50 → $55 | $52.44 | +4.88% | 3 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $55 | $98.36 | -44.08% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $160 | $129.64 | +23.42% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $650 → $670 | $542.36 | +23.53% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $17 → $20 | $5.10 | +292.16% | 3 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,300 → $1,400 | $1,382.85 | +1.24% | 2 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.72 | - | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $60 → $90 | $41.04 | +119.30% | 2 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $270 | $215.75 | +25.14% | 4 | Dec 20, 2023 |
Revvity
Feb 3, 2026
Maintains: Neutral
Price Target: $100 → $105
Current: $99.52
Upside: +5.51%
Adaptive Biotechnologies
Nov 6, 2025
Maintains: Overweight
Price Target: $17 → $20
Current: $16.47
Upside: +21.43%
Henry Schein
Aug 7, 2025
Maintains: Overweight
Price Target: $80 → $76
Current: $77.00
Upside: -1.30%
Avantor
Aug 4, 2025
Maintains: Overweight
Price Target: $17 → $14
Current: $10.79
Upside: +29.75%
Illumina
Aug 1, 2025
Maintains: Neutral
Price Target: $85 → $100
Current: $133.61
Upside: -25.16%
Caris Life Sciences
Jul 14, 2025
Initiates: Overweight
Price Target: $31
Current: $21.25
Upside: +45.88%
10x Genomics
May 9, 2025
Maintains: Neutral
Price Target: $12 → $9
Current: $17.70
Upside: -49.15%
Twist Bioscience
May 6, 2025
Maintains: Underweight
Price Target: $40 → $33
Current: $47.10
Upside: -29.94%
Repligen
Apr 29, 2025
Maintains: Overweight
Price Target: $200 → $190
Current: $139.66
Upside: +36.04%
Envista Holdings
Mar 6, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $24.71
Upside: -23.11%
Mar 6, 2025
Maintains: Neutral
Price Target: $380 → $390
Current: $376.89
Upside: +3.48%
Feb 25, 2025
Downgrades: Neutral
Price Target: $50 → $55
Current: $52.44
Upside: +4.88%
Feb 21, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $98.36
Upside: -44.08%
Nov 26, 2024
Maintains: Overweight
Price Target: $165 → $160
Current: $129.64
Upside: +23.42%
Sep 20, 2024
Maintains: Overweight
Price Target: $650 → $670
Current: $542.36
Upside: +23.53%
Aug 7, 2024
Maintains: Underweight
Price Target: $17 → $20
Current: $5.10
Upside: +292.16%
Aug 5, 2024
Maintains: Neutral
Price Target: $1,300 → $1,400
Current: $1,382.85
Upside: +1.24%
Apr 22, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.72
Upside: -
Feb 14, 2024
Upgrades: Overweight
Price Target: $60 → $90
Current: $41.04
Upside: +119.30%
Dec 20, 2023
Maintains: Overweight
Price Target: $250 → $270
Current: $215.75
Upside: +25.14%